isoxazoles has been researched along with Epstein-Barr Virus Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlow, EA; Bilger, A; Bristol, JA; Delecluse, HJ; Kenney, SC; Li, Z; Ma, S; Nawandar, D; Plowshay, J; Romero-Masters, JC; Tsai, MH | 1 |
| Miyamoto, A; Okamoto, T; Oki, J; Shirai, M; Sugai, R | 1 |
2 other study(ies) available for isoxazoles and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Line, Transformed; Cell Proliferation; Crotonates; Cyclin E; Disease Models, Animal; Epstein-Barr Virus Infections; Gene Expression Regulation; Gene Expression Regulation, Viral; Genes, myc; Herpesvirus 4, Human; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Lymphoproliferative Disorders; Mice; NF-kappa B; Nitriles; Toluidines; Virus Activation; Virus Latency; Virus Replication; Xenograft Model Antitumor Assays | 2017 |
Urine stone formation during treatment with zonisamide.
Topics: Anticonvulsants; Child; Encephalitis, Viral; Epstein-Barr Virus Infections; Female; Hematuria; Herpesvirus 4, Human; Humans; Isoxazoles; Pyuria; Seizures; Urinary Calculi; Zonisamide | 2000 |